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Abstract
OBJECTIVE—We assessed the relationship between phasing out stavudine in first-line 
antiretroviral therapy(ART) in accordance with World Health Organization 2010 policy and single-
drug substitutions (SDS)(substituting the nucleoside reverse transcriptase inhibitor(NRTI) in first-
line ART) in sub-Saharan Africa.
DESIGN—Prospective cohort analysis (IeDEA-Multiregional) including ART-naïve, HIV-
infected patients ≥16 years initiating ART between January 2005-December 2012. Before April 
2010 (July 2007 in Zambia) national guidelines called for patients to initiate stavudine-based or 
zidovudine-based regimen, while after tenofovir or zidovudine replaced stavudine in first-line 
ART.
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METHODS—We evaluated the frequency of stavudine use and SDS by calendar year, 2004-2014. 
Competing risk regression was used to assess the association between NRTI use and SDS in the 
first 24 months on ART.
RESULTS—33,441 (8.9%; 95% CI: 8.7-8.9%) SDS occurred among 377,656 patients in the first 
24 months on ART, close to 40% of which were amongst patients on stavudine. The decrease in 
SDS corresponded with the phasing out of stavudine. Competing risks regression models showed 
that patients on tenofovir were 20% to 95% less likely to require a SDS than patients on stavudine, 
while patients on zidovudine had a 75% to 85% decrease in the hazards of SDS when compared to 
stavudine.
CONCLUSION—The decline in SDS in the first 24 months on treatment appears to be associated 
with phasing out stavudine for zidovudine or tenofovir in first-line ART in our study. Further 
efforts to decrease the cost of tenofovir and zidovudine for use in this setting is warranted to 
substitute all patients still receiving stavudine.
Keywords
antiretroviral therapy; single-drug substitution; low- and middle-income countries; drug toxicities; 
drug side-effects
INTRODUCTION
In sub-Saharan Africa an estimated 11.4 million HIV-positive individuals were receiving 
antiretroviral therapy (ART) by mid-2015[1]. In low- and middle-income countries(LMICs), 
HIV treatment programs take a public health approach that utilizes twelve antiretrovirals in 
four drug classes[2,3]. Since treatment options are limited in LMICs and at least three drugs 
from two drug classes are typically needed for effectiveness, therapeutic options need to be 
maximized. One way to increase the life span of first-line ART in patients in LMICs is by 
decreasing rates of substituting individual drugs, typically for reasons of toxicity, within the 
regimen (“single-drug substitutions(SDS)”).
Prior to the World Health Organization(WHO) guidelines change in 2010, the most 
frequently used nucleoside reverse-transcriptase inhibitor(NRTI) alongside lamivudine was 
stavudine[2,3]. Stavudine is highly effective in treating HIV[4] but is associated with severe 
side-effects[5-7]. In 2009, as a result of stavudine’s poor side-effect profile, the WHO 
recommended replacing stavudine with tenofovir or zidovudine for initial HIV treatment[4]. 
In 2010, most governments in LMICs followed suit and began to phase out stavudine and 
replace it with tenofovir or zidovudine, for all new ART initiates[8]. Since there are fewer 
side-effects and drug toxicities associated with tenofovir and zidovudine than 
stavudine[9-12] the switch was expected to be accompanied by a marked decrease in SDS in 
first-line ART.
To date, several observational studies set in LMICs have compared rates of SDS amongst 
patients on stavudine-, tenofovir- and zidovudine-based regimens. All studies found that 
patients on tenofovir had about an 82% decrease in the risk of SDS(summary risk ratio 
(RR):0.18; 95% confidence interval (CI):0.15-0.20) compared to patients on 
stavudine[13-21], while patients on zidovudine, although at higher risk of SDS compared to 
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tenofovir, remained at lower risk of substitution compared to patients on stavudine(summary 
RR:0.41; 95%CI:0.37-0.45)[13-18].
While previous observational studies do suggest tenofovir and zidovudine are associated 
with fewer SDS compared to stavudine[13-21], many had important limitations. Two 
studies[13,14] had patient populations that initiated tenofovir prior to implementation of the 
2010 WHO policy change. These patients would be more likely to have initiated tenofovir 
because of contraindications to stavudine or zidovudine leading to strong confounding by 
indication. We sought to use one of the largest HIV database in the world to assess whether 
or not the phasing out of stavudine in first-line ART in accordance with WHO 2010 policy 
decreased SDS in sub-Saharan Africa. This transition allows evaluation of the impact of a 
major policy change while accounting for secular trends in improvements in HIV treatment.
METHODS
Cohort Description
The International epidemiological Databases to Evaluate AIDS (IeDEA, www.iedea.org) is a 
world-wide National Institute of Health sponsored collaboration of HIV treatment cohorts. 
This study included cohorts from Southern Africa, East Africa and West Africa[22]. Data is 
collected on patients at the start of ART and at each follow-up visit. Clinic information 
includes demographic, clinical and HIV regimen data. Before April 2010(2007 in Zambia), 
if a patient experienced side-effects or toxicities related to stavudine or zidovudine, and was 
not in need of second-line therapy, the recommendation was to substitute stavudine with 
either zidovudine, if no related anemia or neutropenia was present, or abacavir and to 
substitute zidovudine with either stavudine or abacavir[23-29]. After April 2010(2007 in 
Zambia) patients initiated onto stavudine or zidovudine now had tenofovir, if no signs of 
renal-insufficiency were detected, while those initiated onto tenofovir could substitute with 
stavudine, zidovudine, or abacavir[23-29].
All IeDEA sites obtained ethical approval from relevant local institutions before contributing 
anonymized patient data. Approval for analysis of de-identified data was granted by Boston 
University’s Institutional Review Board.
Study design
We performed a cohort analysis of data collected prospectively as part of routine care at 
clinics in the IeDEA multiregional collaboration. We included ART-naïve, HIV-infected 
patients ≥16 years old initiating first-line ART between January 1 2005-December 31 2012 
for all countries except Nigeria, where patients initiating ART between January 1 2007-
December 31 2012 were included as the roll out of ART started later. All patients had the 
potential for 24 months of follow-up. Prior to April 2010 national HIV treatment guidelines 
recommended the use of stavudine or zidovudine in first-line ART in all six included 
countries, thereafter, guidelines called for tenofovir or zidovudine to replace 
stavudine[23-27]. The only exception was in Zambia, which switched from stavudine or 
zidovudine to tenofovir in July 2007[28,29].
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Study variables
All demographic (i.e. age, sex, clinic and country) and clinical (i.e. year of ART initiation, 
CD4 count, hemoglobin levels, weight, WHO stage, first-line NRTI (stavudine, zidovudine 
or tenofovir) and non-nucleoside reverse transcriptase inhibitor (NNRTI)(nevirapine or 
efavirenz) characteristics measured at ART initiation came from routinely collected clinic 
data. WHO staging was not available for East African countries.
The primary outcome variable was the proportion of patients who underwent a SDS in the 
first 24-months on ART. Follow-up time of 24-months was chosen as monitoring and time to 
development of toxicity/side-effects differ between drugs. Laboratory monitoring for 
tenofovir and zidovudine is conducted early on after treatment initiation, while for stavudine 
monitoring begins more often when the patient begins to develop clinical symptoms of 
toxicity(up to 24-48 months on ART[30]) diagnosed at a medical visit[2,3]. SDS was 
defined as substitution of the NRTI only within first-line ART. The reason for SDS were not 
available.
Statistical analysis
Patient characteristics at ART initiation were summarized with descriptive statistics and 
stratified by country. To look for trends in the use of stavudine in first-line ART and SDS 
over time, proportions of patients initiating stavudine or having a SDS in the first 24 months 
on ART were stratified by country and year of ART initiation and plotted from January 1 
2005-December 31 2012, separately, with Nigeria being the exception, as data collection 
began in 2007. To test an additional hypothesis that tenofovir was being used among patients 
with contraindications to stavudine prior to guideline change, we looked at rates of SDS by 
NRTI over time.
Fine and Gray’s competing risks regression method[31] was used to identify if the choice of 
NRTI in first-line ART was a predictor of SDS in the first 24 months on ART, accounting for 
attrition as competing risks and adjusted for age, sex, year of ART initiation, CD4 count, 
hemoglobin levels, WHO stage, and first-line NNRTI depending on country, with robust 
estimates at site level. We ran two models for each country. In both, we included all 
demographic and clinical characteristics at treatment initiation and year of ART initiation. 
The models differed as year of treatment initiation and NRTIs used are highly associated and 
therefore each model used only one of the two. Follow up time began at ART initiation and 
ended at the earliest of: 1) SDS; 2) initiation of second-line ART; 3) discontinuation of 
treatment 3) loss to follow-up (defined as not attending the clinic in the last 6 months); 4) 
death; 5) transfer; 6) completion of 24-months of follow-up; or 7) or date of dataset 
closure(December 31 2014).
We assessed interaction between gender and NRTI, CD4 count and NRTI, hemoglobin levels 
and NRTI, CD4 count and gender, WHO stage and gender and hemoglobin levels and 
gender on the additive scale by calculating the risk due to interdependence (R(I))[32].
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Bayesian analysis
As this is not the first study on the topic and we can draw stronger conclusions when 
incorporating those prior results into our current analysis, we conducted a Bayesian analysis 
which allows incorporation of the result of prior knowledge about the relationship between 
the exposure and the outcome into the estimation of parameters. Our approach to Bayesian 
analysis[33] is essentially a weighted average incorporating the prior distribution (previous 
literature) and our data. To do this, point estimates and corresponding 95% confidence 
intervals (CI) for priors were obtained from previous publications assessing predictors of 
SDS[13-21]. Ratio measures for each potential predictor of SDS (age, sex, clinic, CD4 
count, weight, hemoglobin levels, WHO stage, NRTI and NNRTI used in first-line regimen) 
were extracted from the existing literature. We performed a meta-analysis using random 
effects models, due to heterogeneity in estimates, to first create weighted summary estimates 
for each individual predictor, separately, from the existing literature (referred to as the 
“prior”). The same technique was used to calculate the summary estimates of each 
individual predictor, separately, from our data (referred to as the “likelihood”) and then 
combined the prior and likelihood estimates for each predictor, separately, to calculate a 
combined summary estimate (referred to as the “posterior”) and corresponding Bayesian 
credible intervals(CrI).
Sensitivity analysis
As we may have had unmeasured confounding in our population we conducted a 
multidimensional sensitivity analysis[34], by making assumptions about the strength of the 
effect of an unmeasured confounder on SDS and its prevalence in both patients on tenofovir 
or zidovudine (exposed) and those on stavudine (unexposed). We were interested in whether 
the confounder would overestimate the effect of exposure to tenofovir or zidovudine. We 
considered a confounder that would increase SDS and was more prevalent in patients on 
stavudine. We then back-calculated the relative risk we would have observed had we 
collected data on and adjusted for the purported confounder[34].
Multiple imputation
To account for missing data, we used multiple imputation by chained equations method 
using PROC MI in SAS[35] and assumed that the data were missing at random[36]. All 
models were fitted using 25 imputed datasets and estimated coefficients combined by 
averaging with the MIANALYZE procedure in SAS[37]. All clinical and demographic 
variables were included in the imputed models in addition to the outcome of SDS and 
indicator variables for death and loss to inform the missingness, but were not imputed. 
Appropriate standard errors were calculated using the within and between imputation 
standard errors of the estimates using Rubin’s rules[36]. Since models based on imputed 
results did not differ from the models on the original data we displayed the results based on 
the original data.
RESULTS
We included 377,656 patients in the analysis (Table 1), 24% initiated a stavudine-based ART 
regimen, ranging from from 25% in Zambia and Uganda to 60% in South Africa. Zambia 
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contributed the largest number of patients (n=205,140) and Nigeria the smallest (n=7,434). 
Demographic and clinical characteristics were similar across countries. Patients were 
predominately female (62.9%) with a median age of 35.2 years (interquartile range (IQR):
29.8-42.0) and a median time on treatment of 24.0 months (IQR:12.1-24.0), which did not 
differ by cohort. At ART initiation patients had a median CD4 count of 155 cells/mm3 (IQR:
74-241), with patients in South Africa having the lowest median (130 cells/mm3;IQR:
58-199) and Nigeria the highest (192 cells/mm3;IQR:91-312).
When stratified by year, gender, weight and age remained unchanged over time, while 
patients’ cellular immunity at ART initiation improved in all countries. Additionally, the 
proportion of patients with tuberculosis and WHO III/IV stage declined over time in South 
Africa. Over 70% of patients in all countries remained alive and in care over 24 months on 
treatment. Overall attrition(combination of death and loss to follow-up) was 17.8% (95%CI:
17.7-17.9%) and fairly consistent across countries with, Zambia having the lowest rate of 
attrition in the first 24 months on ART at 15.3% (95%CI:15.2-15.5%) and Nigeria the 
highest at 23.5% (95%CI:22.5-24.4%)
Compliance with WHO guidelines: phasing out of stavudine in first-line ART
All countries, with the exception of South Africa where, in 2009, 95% of patients still 
initiated stavudine, began phasing out stavudine prior to the WHO guidelines making the 
change in 2010 (Figure 1). Zambia, Kenya and Uganda, began replacing stavudine with 
zidovudine in first-line ART as early as 2007 (2005 in Zambia), potentially in parallel with 
the WHO’s recommendation for lower dose stavudine use (30mg instead of 40mg[38]). 
Tenofovir was introduced after the WHO recommended its use in first-line therapy in 2010 
(2007 in Zambia), as such, within two years of the change in 2012, fewer than 10% of 
patients were being initiated on stavudine. Prior to 2010 in Cote d’Ivoire and Nigeria, 
stavudine and zidovudine were used interchangeably, while stavudine use decreased 
substantially, with less than 10% of patients initiating the drug after 2010, when both 
countries decided on zidovudine as the NRTI of choice in first-line ART. Tenofovir had yet 
to be introduced in first-line ART in Cote d’Ivoire or Nigeria before 2012 due to cost[3].
Decrease in SDS associated with the phase out of stavudine
While the WHO policy change was accompanied by a clear shift away from stavudine to 
tenofovir, the impact on single drug substitutions is less clear. Overall, SDS affected 
8.8%(95%CI:8.7-8.9%) of patients in the first 24 months on ART with 38% of SDS related 
to stavudine compared to 49% and 13% related to zidovudine or tenofovir, respectively. The 
decrease in SDS was associated with the phasing out of stavudine in first-line ART, 
decreasing from an overall rate of 11.3%(95%CI:11.2-11.4%) prior to 2010 when 55% of 
patients were initiating stavudine to 5.4%(95%CI:5.3-5.5%) after 2010 when only 7.4% of 
patients initiated treatment with this drug. However, it is important to note that in all 
countries SDS began roughly two years prior to the WHO guideline change in 2010(Figure 
2). For all countries competing risks regression models adjusted for year confirmed our 
results, showing a decrease in the hazards of SDS in accordance with the decrease in the use 
of stavudine(Supplementary Table 1).
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SDS stratified by initiating NRTI and substitution NRTI
In addition to the variation observed in relation to the policy change, we also observed 
differences in rates of substitution by treatment regimen. Patients initiating stavudine(13.9%; 
95%CI:13.7-14.1%) and zidovudine(12.0%; 95%CI:11.8-12.2%) had higher rates of single 
drug substitution compared to patients initiating tenofovir(2.8%; 95%CI:2.7-2.9%). Also, 
while rates of substitution decreased over time for patients on tenofovir, they remained 
stable for zidovudine patients and increased for those on stavudine(Supplementary Figure 1). 
All countries followed the national ART guidelines outlining the antiretrovirals eligible for 
substitution. These included tenofovir, stavudine, zidovudine or abacavir dependending on 
NRTIs included in the first-line regimen with the occasional use of didanosine as an 
alternative(Supplementary Figure 2). Zidovudine was the most common SDS used for both 
tenofovir(50%; 95%CI:48.6-51.6%) and stavudine(67.9%; 95%CI:67.2-68.6%), while 
stavudine was the SDS for a zidovudine-based first-line regimen(65.1%; 95%CI:
64.2-66.0%).
Consistent with known toxicity patterns, SDS occurred earlier for patients on 
zidovudine(median 8.1 months after start of treatment; IQR:2.3-17.0) and tenofovir(median 
10.2 months after start of treatment; IQR:3.6-18.1) compared to stavudine(median 14.2 
months; IQR:7.3-19.6) after start of treatment.
Changing the NRTI used in first-line ART could explain the temporal trends in SDS
Adjusted competing risks regression models evaluating the association between choice of 
NRTI used in first-line ART and SDS helped us to confirm that the decrease in rates of SDS 
was associated with the phasing out of stavudine for tenofovir or zidovudine in first-line 
ART. Adjusted models showed that patients initiating tenofovir in Southern and East Africa 
were 20% to 95% less likely to undergo a substitution than patients initiating 
stavudine(Table 2). Posterior Bayesian estimates using an informative prior, showed close to 
an 80% reduction in the risk of SDS(posterior risk ratio (RR):0.21; 95% credible 
interval(CrI):0.20-0.22) when comparing tenofovir to stavudine (Table 3). With the 
exception of Zambia, where we saw an increase in the hazards of SDS when comparing 
zidovudine to stavudine(hazard ratio (HR):2.59; 95%CI:2.3-3.0) and Kenya, where we saw 
no association(HR:1.13; 95%CI:0.99-1.28)(Table 2), patients on zidovudine compared to 
stavudine in Uganda, Cote d’Ivoire and Nigeria had a 75% to 85% decrease in the hazards of 
SDS when compared to stavudine. Posterior Bayesian estimates using an informative prior, 
showed close to a 70% reduction in the risk of SDS(posterior RR:0.31; 95%CrI:0.30-0.33)
(Table 3).
Our results also suggest that females compared to males have a 50% increase in the risk of 
SDS(posterior RR:1.48; 95%CrI:1.43-1.52)(Table 2 and Table 3). Since we believed changes 
in the trends of substitutions for sex could vary by NRTI used in first-line ART we 
calculated the risk due to interdependence(R(I)). With the exception of Zambia and Kenya, 
where the R(I) was essentially zero, in the other four countries showed a positive 
interdependence (Uganda 2%; Cote d’Ivoire 4%, South Africa 5% and Nigeria 6%). In other 
words, in Nigeria for example, 6% of SDS in women on stavudine is related to the dual 
action of female gender and stavudine. The risk of SDS in the doubly exposed(females 
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exposed to stavudine) was 41.9% vs the risk of 6.0% in the doubly unexposed(males 
unexposed to stavudine). We did not see any signs of interaction when assessing all other 
biological relationships using the R(I).
We saw inconsistent results when comparing nevirapine to efavirenz. In Zambia, Kenya, 
Uganda and Nigeria patients on nevirapine had a 10% to 70 % increase in the risk of SDS 
compared to those on efavirenz, while patients in South Africa and Cote D’Ivoire had a 
decrease in SDS of 20% and 40%, respectively. We also saw a decrease in the risk of SDS 
by 10% to 40% in in all countries amongst patients with CD4 count <100 cells/mm3 
compared to ≥100 cells/mm3.
Bias Analysis
Bias analyses simulating a confounder that would overestimate the effect of tenofovir or 
zidovudine vs. stavudine showed that in order for adjustment for an unmeasured confounder 
to bring our results close to null, the confounder would have to be present in 5% in those 
exposed to tenofovir or zidovudine, extremely common among patients exposed to 
stavudine(40%) and be a very strong predictor of SDS(RR >11.3), highly unlikely 
(Supplementary Table 2).
DISCUSSION
In the largest study to date, across multiple countries on the African continent, we show 
steady decrease in SDS corresponding to the phasing out of stavudine, in accordance with 
the WHO guidelines, from an overall rate of 11% prior to 2010 when 55% of patients were 
initiating stavudine to 5% after 2010 when only 7% of patients initiated treatment with this 
drug. Using Bayesian methods[33], although high heterogeneity between studies for the 
majority of estimates, we were able to estimate an 80% decrease in the risk of SDS when 
comparing tenofovir to stavudine, and 70% decrease when comparing stavudine to 
zidovudine, further highlighting the better safety profile associated with tenofovir and 
zidovudine compared to stavudine. Our results also showed a decrease in the rates of SDS 
from 2005 to 2012 for patients on tenofovir, providing evidence to support the notion that 
patients in earlier years where being initiated on tenofovir due to contraindications to 
stavudine or zidovudine and therefore at higher risk of toxicity/side-effects.
Time to substitution varied depending on the NRTI used in first-line ART, with zidovudine 
and tenofovir occurring early after treatment initiation and at a higher rate later on in follow-
up amongst patients on stavudine. This is consistent with previous studies conducted in sub-
Saharan Africa[13-21], however, it is important to note that time to substitution is partly a 
function of the frequency of monitoring, which differs for each NRTI. Laboratory 
monitoring for tenofovir and zidovudine is often conducted early on after treatment 
initiation, while for stavudine monitoring begins more often when the patient begins to 
develop clinical symptoms of toxicity diagnosed at a medical visit[2,3]. Additionally, 
although national guidelines for substitution of the NRTI and NNRTI within first-line ART 
were the same, the difference in estimates when comparing zidovudine to stavudine and also 
nevirapine to efavirenz could be due to variation in monitoring practices or the availability 
of NRTIs for substitution in each country.
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Females, compared to males, had a 50% increase in the risk of SDS in our study, consistent 
with previous research[13,15-20]. By assessing effect measure modification on the additive 
scale, we also showed that depending on country, 2% to 6% , of SDS in women on stavudine 
was related to the dual action of female gender and stavudine. Although we could not 
confirm the reason for substitution in our study, previous research has reported women on 
stavudine are at higher risk of toxicity/side-effects than men[30,39,40] and that differences 
in risk of toxicity observed between genders could be related to differences in susceptibility 
or to a higher level of adherence to therapy achieved by women[30]. In addition to the size 
of our study population, we are the first to evaluate trends in SDS over almost a decade of 
treatment in public sector since the roll out of ART in 2004 in six countries in sub-Saharan 
Africa. However, our findings should be considered in light of the study limitations. First, 
this study represents patients from urban areas. Although some clinics are run out of tertiary 
hospitals, the majority operate at the primary care level, are led by nurses or clinical officers 
rather than physicians and are part of the public health care system of the country and may, 
therefore, not be generalizable to other clinics. Second, there was variability in the estimates 
of the association between NRTI used in first-line ART and SDSs by country. When 
comparing tenofovir to stavudine we saw a 20% to 95% decrease in the hazards of SDS and 
when comparing zidovudine to stavudine we saw an 85% reduction to a 200% increase in 
the hazards of SDS. Although national guidelines for substitution of the NRTI within first-
line ART were the same in all six countries, the difference could be due to variation in 
monitoring practices at the level of the clinic or clinician or the availability of alternative 
NRTIs used for substitution. Third, due to the lack of documentation of reasons for SDS for 
almost 95% of events amongst patients with the event, we are likely underestimating the 
frequency and type of side effects due to less than perfect surveillance. There is a chance 
SDS in our study were driven by the policy change and not by side-effects/toxicity of 
stavudine. When conducted this study in our pediatric population we did see a substantial 
spike in SDS around the time of the guideline change as clinicians were substituting 
stavudine, regardless if the patient was tolerating stavudine well, with zidovudine or 
tenofovir. If substitutions were being driven by the guidelines in adults we believe we would 
see a similar increase, which is not present in these data. Fourth, patients with lower CD4 
count (<100 cells/mm3) had upwards of 40% decrease in the risk of SDS over the follow-up 
period in some countries. As we do see higher rates of attrition in patients with a lower CD4 
count (<100 cells/mm3 - 23.6% vs. ≥100 cells/mm3 - 14.2%), the decreased risk amongst 
patients with poorer immune status could be caused by survivor bias. Fifth, in order to 
strengthen the argument for further reduction in the cost in tenofovir and zidovudine for use 
in LMICs we recognize that it would be important to know the proportion of individuals 
who are symptomatic with toxicity related to stavudine-based therapy and did not experience 
a SDS. Unfortunately, conditions are poorly captured in the database preventing us from 
accurately assess symptoms amongst patients who did not have a SDS. However, Figure 1 
shows that the policy change switching to tenofovir was the reason for the decline in SDSs 
in South Africa, as the country went from almost 100% of patients initiating stavudine prior 
to the 2010 guidelines changing to <10%, which we believe allowed us to evaluate what a 
change in national policy to included tenofovir in first-line ART might do in other countries 
as they make the change. Sixth, it is possible that our populations differed with respect to 
some unmeasured confounder, as data on WHO staging were not available for Kenya and 
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Uganda. We may therefore have residual confounding in our estimates from those countries. 
However, our bias analysis suggests such an unmeasured confounder would be extremely 
unlikely in our cohort. Finally, multiple imputation helps make it possible to handle missing 
data routinely and improve the validity of research. However, deviations from the 
assumptions needed[35] could have led to unpredictable biases in our parameter estimates.
Conclusion
The decline in SDS in the first 24 months on treatment is associated with phasing out of 
stavudine for zidovudine or tenofovir in first-line ART in the countries in our study. When 
calculating the number needed to treat we found that to prevent one additional SDS event six 
patients would need to be treated over 24 months, which would be considered beneficial. 
Supporting further efforts to decrease the cost of tenofovir and zidovudine for use in LMICs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Trends in the stavudine use in first-line antiretroviral therapy for treatment naïve 
patients stratified by country and year since ART guidelines changed (N=377,656)
*Dashed lines represents the change in national guidelines to introduce zidovudine or 
tenofovir into first-line ART (2007 for Zambia and 2010 for all other countries)
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Figure 2. Proportion of single-drug substitutions over the first 24-months on antiretroviral 
therapy stratified by year of since ART guidelines changed for all countries (N=377,656)
*Dashed lines represents the change in national guidelines to introduce zidovudine or 
tenofovir into first-line ART (2007 for Zambia and 2010 for all other countries)
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